CompletedNCT00498173

Targeted Pharmacologic Interventions for Autism: A study of Atomoxetine in Children and Adolescents With Autism

It tested atomoxetine for Autism.

ADHD, AutismDrugFrom 5 Years to 15 Years

The study in practice

Understand this study

Listed age limits: 5 years to 15 years.

Listed locations: Indianapolis, United States · Lexington, United StatesSee all locations and recruitment

Compensation and expense reimbursement have not been verified for this summary.

Study clarity

Study start dateJuly 2007

Recruitment status: Completed
Enrollment listed in the registry: 60
Sponsor: Massachusetts General Hospital
Sponsor type: Hospital / academic medical center
Study type: Drug
Intervention type: Medication / drug
Study phase: Phase 3
Locations: United States
Age range: From 5 Years to 15 Years
Official registry ID: NCT00498173
Official title: Targeted Pharmacologic Interventions for Autism: A Double-Blind, Placebo-Controlled Trial of Atomoxetine in Children and Adolescents With Autism

Completed

Indianapolis · Lexington

FAQ

Who is behind this study?

The study sponsor is Massachusetts General Hospital, a hospital or academic medical center.

Did this study involve medication?

Yes. The study involved medication, including Atomoxetine and Placebo.

Who was this study for?

Listed age limits: 5 years to 15 years.

Explore other studies

Answer a few simple questions to explore HopeStage studies by condition, country, and situation.